Business Context and Reporting Period
This Form 8-K was filed by TherapeuticsMD, Inc. on April 27, 2022. The report addresses a critical corporate governance event regarding the company's continued listing on the Nasdaq Global Select Market.
Key Financial Metrics
This filing is a current report regarding a corporate action and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Corporate Actions
- Nasdaq Non-Compliance: The company received a determination from Nasdaq stating it had not regained compliance with the minimum bid price requirement of $1.00 per share.
- Listing Extension: Following a hearing on April 14, 2022, the Nasdaq Hearings Panel granted the company an extension to maintain its listing through June 1, 2022.
- Reverse Stock Split: To regain compliance, the Board of Directors approved a 1-for-50 reverse stock split.
- Capital Structure Adjustment: The authorized shares of Common Stock will be reduced from 600,000,000 to 12,000,000 shares.
- Implementation Timeline: The split is expected to be effective on or about May 6, 2022, with post-split trading commencing on May 9, 2022, under the symbol "TXMD".
- Fractional Shares: Fractional shares resulting from the split will be rounded up to the nearest whole share.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the successful consummation of the reverse stock split and the maintenance of the Nasdaq listing. Management notes that actual results may differ due to risks and uncertainties, including the possibility of failing to maintain the listing or unforeseen effects of the reverse stock split. The company explicitly states it undertakes no duty to update these forward-looking statements.
Investor Verification Checklist
- Verify the effective date and time of the 1-for-50 reverse stock split (expected May 6, 2022).
- Confirm the trading resumption date for post-split shares (expected May 9, 2022).
- Review the company's most recent Form 10-K and 10-Q for detailed risk factors and financial health, as this 8-K does not provide financial data.
- Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement by the June 1, 2022 deadline.
- Check for any subsequent filings regarding the final authorization of the Certificate of Change for the reverse split.